SCHEMBL1745335

SCHEMBL1745335

CCCN(Cc1ccc(COc2ccc(CCC(=O)OC)cc2)cc1)c1nc2c(s1)CCc1ccccc1-2

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 7/20 0.41
PPARG P37231 3/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
VDR P11473 1/20 0.40
KARS1 Q15046 1/20 0.39
PPARA Q07869 1/20 0.39
POLB P06746 1/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KMT2A Q03164 1/20 0.38
BCHE P06276 2/20 0.37
ALOX5 P09917 1/20 0.37
XIAP P98170 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1633772 0.92 PPARD (0.49) PPARDPPARGPPARABCHE
SCHEMBL1745514 0.82 PPARD (0.46) PPARDPPARGVDRKARS1PPARA
SCHEMBL1746697 0.80 PPARD (0.44) PPARDPPARGVDRKARS1PPARA
SCHEMBL1746767 0.78 ALDH1A1 (0.44) KDM4EALDH1A1HPGDPOLBLMNA
SCHEMBL1745481 0.76 NPSR1 (0.47) PPARDALDH1A1VDRKMT2ABCHE
SCHEMBL1744702 0.74 PPARD (0.54) PPARDPPARGPPARA
SCHEMBL3911613 0.73 PPARD (0.47) PPARDPPARGVDRKARS1BCHE
SCHEMBL3913901 0.72 VDR (0.48) PPARDPPARGVDRPPARABCHE
SCHEMBL1747259 0.71 MEN1 (0.48) PPARDPPARGALDH1A1VDRPPARA
SCHEMBL1747398 0.71 PPARD (0.54) PPARDPPARGPPARALMNABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR PPARD 326/4885PPARG 225/4885KDM4E 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.